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Background/aim: The aim of this study is to determine the effects of different concentrations of albendazole and lansoprazole, which
were benzimidazole derivatives, on endocrinologic and biochemical parameters in experimental type 2 diabetic (T2D) rats.
Materials and methods: In this study, 46 male Wistar Albino rats were used. Animals were divided as healthy control (0.1 mL/rat/day
saline, s.c, n = 6), diabetes control (0.1 mL/rat/day saline, s.c, n = 8), diabetes+low-dose albendazole (5 mg/kg, oral, n = 8), diabetes+highdose albendazole (10 mg/kg, oral n = 8), diabetes+low-dose lansoprazole (15 mg/kg, subcutaneous, n = 8), and diabetes+high-dose
lansoprazole (30 mg/kg, subcutaneous, n = 8). All groups were treated for 8 weeks. The blood samples were analyzed by autoanalyzer
and ELISA kits for biochemical and endocrinological parameters, respectively.
Results: Glucose, HbA1c, triglyceride, low density cholesterol (LDL), leptin, and Homeostatic Model Assessment for insulin resistance
(HOMA-IR) levels increased and insulin and HOMA-β levels decreased in the diabetic rats compared to the healthy control group.
The glucose, HbA1c, and triglyceride levels were partially decreased; however, insulin and HOMA-β levels were increased by low-dose
albendazole therapy. The high dose of lansoprazole treatment increased insulin level.
Conclusion: The lansoprazole and albendazole treatments can be a potential drug or combined with antidiabetic drugs in T2D
treatment by Adenosine 5′-monophosphate activated protein kinase (AMPK), peroxisome proliferator-activated receptor (PPAR),
incretin-like effect and other antidiabetic mechanisms. It may be beneficial to create an effective treatment strategy by developing more
specific substances with benzimidazole scaffold.
Key words: Benzimidazole, HOMA-β, diabetes, antiabetic, rat

1.Introduction
Type 2 diabetes is defined as a chronic inflammatory
metabolic disease that is characterized with the impaired
insulin effect and high blood glucose level [1]. The disease
has degenerative effects on many tissues and a high
incidence worldwide. Although many drugs are used for
the treatment of this disease, more effective treatment
strategies have yet to be found [2,3].
Adenosine 5′-monophosphate activated protein kinase
(AMPK) is considered to be an important potential
therapeutic target for the treatment of type 2 diabetes
(T2D). AMPK is defined as serine/threonine protein
kinase complex. The kinase consists catalytic α (α1, α2),
regulatory β (β1, β2), and regulatory γ (γ1, γ2, γ3) subunits
and express in each tissue [3]. Although the isoforms have
been reported to have different effects and tissue-specific,
the effects of isoforms have not been fully cleared. However,

α1 isoform predominates in the liver and adipose tissue;
whereas, α2 predominates in the brain, heart, and skeletal
muscles [4]. The AMPK acts as a sensor that determines
the AMP/ATP or ADP/ATP ratio. The AMPK is activated
by phosphorylation of Thr-172 residue in the α subunit and
increasing AMP/ATP ratio in the cell [3-6]. The activated
AMPK provides the phosphorylation of key metabolic
proteins that inhibits anabolic activities and increase
catabolic activities [3]. The AMPK activation suppresses
genes mediating gluconeogenesis and lipogenesis in the
liver [7], and the activation of AMPK has been reported
to increase insulin secretion from pancreatic β cells [3,8].
On the contrary, the excessive increased insulin, leptin and
diacylglycerol levels and hyperglycemia, hyperlipidemia
inhibit the AMPK activation [6]. Therefore, the AMPK
activation increases insulin sensitivity, stimulates glycogen
synthesis while inhibits glycolysis. Thus, it is an important
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therapeutic target for glucose hemostasis in the treatment
of T2D patients [3,4,6,8].
Metformin, one of the most important antidiabetics,
provides indirect activation of AMPK [3,7]. In addition,
thiazolidinedione, which is also an antidiabetic drug and
nondrug ginsenosids, berberine, quercetin, and resveratrol
indirectly activate the AMPK [3,9]. Recently, potential
antidiabetic agents (AICAR, A769662, PT1, C24, MK-8722,
PF-06409577, ex229, PF-06409577 and benzimidazole
compound 991) that enable the AMPK activation of skeletal
muscles and liver have been tested for T2D treatment [3].
The ex229, newly developed benzimidazole derivative and
the AMPK activator, stimulates glucose entry into skeletal
muscles and increases oxidation of fatty acids in skeletal
muscles. Moreover, the antidiabetic effects of ex229 are
variable as depending on the dose [10]. Metformin has also
been shown to reduce insulin resistance, hyperglycemia,
and it increases dose-dependent glucose entry into the
cell by the dose-dependent effect and the indirect AMPK
activation [11]. Metformin contributes to glucagonlike peptide (GLP)-1 secretion by AMPK activation and
potentiates reducing blood glucose [12]. Metformin has
inhibited the lipogenesis and gluconeogenesis, and it
regulates the glucose transport, glycolysis, glycogenesis
and fatty acid oxidation by activating AMPK α1 and α2
transcription in fish fed a high with energy diet [13].
Metformin and AICAR administration have restricted
the hepatic production of glucose by the phosphorylation
of Thr172 region of the AMPK [14]. Antidiabetic drugs
troglitazone and pioglitazone have increased glucose entry
into muscle cells and fatty acid oxidation in muscle cells
by the AMPK activation. Also, troglitazone has activated
the AMPK signal in liver and adipose tissue and increases
AMP/ATP ratio [15].
Albendazole, a benzimidazole derivative, is generally
used as an anthelmintic in most mammals. It is defined
as an enantiomeric drug. Albendazole is converted to the
sulfoxide structure in the liver and distributes widely to
tissues [16]. In addition, albendazole has been reported
to provide the AMPK activation in vitro and in vivo [17].
Lansoprazole, another benzimidazole derivative, has
been used for the treatment of diseases such as ulcers and
esophagitis for about 27 years [18]. Although lansoprazole
is not reported the direct effect on the AMPK, it regenerates
and sensitizes beta cells, induces peroxisome proliferatoractivated receptor-γ (PPARγ) through incretin and the
regulation of lipid metabolism, and increases the insulin
synthesis and adiponectin/leptin ratio [19-22]. In addition,
its high doses decrease glucose, triglyceride levels, and
stimulate beta cells by increasing incretin secretion,
providing β cell regeneration and neogenesis, delaying
gastric emptying [19-23].
In recent years, alternative treatment strategies have
been tried in the treatment of T2D. Benzimidazole-

derived substances have antidiabetic potentials by
affecting different mechanism, especially the AMPK
pathway. The aim of this study was to determine the
efficacy of benzimidazole-derived albendazole (5 mg/kg
and 10 mg/kg) and lansoprazole (15 mg/kg and 30 mg/kg)
on different endocrinological and biochemical parameters
in experimental T2D rats.
2.Materials and methods
2.1. Animals
The study was carried out on 46 healthy male Wistar
Albino rats aged 8-12 weeks. The fasting blood glucose
and basal lipid profiles of rats were determined before
the study. Feed and water requirements were met as ad
libitum. The composition of the ration given to the healthy
control group is as follows: dry matter: 89%, crude protein:
21%, cellulose: <5%, ash <10%, Ca: 1%–2%, P: 0.5%–1%,
NaCl: 0.5%, ME: 2850 kcal/kg. The animals were housed
in Selçuk University Chair of Experimental Medicine
Research and Application Center (SUCEMRAC), Konya,
Turkey. Research protocol was reviewed and approved by
the Ethic Committee of SUCEMRAC (Approved number:
2017-41).
2.2. Induction of Type 2 diabetes
Experimental Type 2 diabetes (T2D) model was induced
according to the method proposed by Srinivasan et al
[24]. In this method, rats were fed by high fat diet (HFD,
containing 58% fat, 25% protein and 17% carbohydrate, as
a percentage of total kcal) ad libitum for 2 weeks. HFD
composition included 37% animal fat as tallow, 30.5% corn,
3% vegetable oil, 20% casein, 4.5% soy pulp, 1.7% dicalcium
phosphate, 0.2% dl-methionine, 1.6% limestone, 0.5% salt,
and a vitamin-mineral blend 1%. The streptozotocin (STZ,
35 mg/kg, s.c.) were administered to rats after the 2 weeks.
Before injection, streptozotocin (STZ, ≥98%, analytical
purity, Sigma-Aldrich Corp., St. Louis, MO, USA) was
dissolved in citrate buffer (pH 4.5, 20 mg/mL). After the
injection, 5 % dextrose was supplemented to prevent the
animal from fatal hypoglycemia for 24 h. The rats with the
nonfasting glucose level of ≥300 mg/dL were considered
as diabetic on 5 days following STZ injection. The diabetic
rats were fed by HFD ad libitum until the end of the study.
2.3. Drug preparation
Albendazole
was
used
commercially
solution
(Vermiprazole 10%, oral solution, Hipra, Spain)
formulation. Lansoprazole (≥98%, analytical purity) was
provided in powder form from Tokyo Chemical Industry
(Product Number-L0233, Japan). Lansoprazole was
dissolved in solution containing 0.9% sodium chloride
and 0.05% sodium hydroxide in water as 30 mg/mL. After
preparing the stock solutions of the drugs, they were
diluted with 0.9% sodium chloride to the appropriate
dosage amounts.
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The doses of the drugs, which were chosen according to
EMEA data, used in the current research were determined
experimentally in the experimental research, and the
standard doses were indicated in the drug package insert.
2.4. Experimental design
The rats were housed in standard polypropylene cages
during the study. The light (12/12 h light/dark cycle),
temperature (22 ± 2 ° C) and humidity (55 ± 5%) of the
room were maintained under control. All the rats were
grouped as follows.
The saline (0.1 mL/rat/day, s.c.) solution were
administered to group 1 (Healthy control, n = 6) and group
2 (Diabetes control, n = 8) during the experiment. Group
3 [Diabetes+Low-Dose Albendazole (n: 8)] and group
4 [Diabetes+High Dose Albendazole (n: 8)] received
albendazole at 5 mg and 10 mg/kg/day by oral for 8 weeks,
respectively. Group 5 [Diabetes+Low-Dose Lansoprazole
(n: 8)] and group 6 [Diabetes+High Dose Lansoprazole (n:
8)] received lansoprazole at 15 mg and 30 mg/kg/day by
subcutaneously for 8 weeks, respectively.
The healthy control rats were fed with the commercially
available rat normal pellet diet, and all of the diabetic rats
were fed with HFD and all of the rats drank water ad
libitum. The blood samples were collected by retro-orbital
sinus at the end of week 8 under thiopental Na anesthesia
(40 mg/kg, i.p.) and separated as serum. Then, the animals
were euthanized by cervical dislocation. The whole blood
samples for HbA1c were analyzed immediately while the
serum samples were stored at -800 C until analysis.
2.5. Biochemical, endocrinological, and antioxidant
capacity analysis
Biochemistry
parameters
(HDL:
high
density
cholesterol, LDL: low density cholesterol, AST: aspartate
aminotransferase, ALT: alanine aminotransferase, glucose,
urea, creatinine, cholesterol, triglyceride) in serum samples
and HbA1c (Hemoglobin A1c) parameter in whole blood
samples were analyzed by the autoanalyser (BT-300
plus, Rome, Italy) and HPLC (Primus Primatech USA),
respectively. Insulin (Ultra Sensitive Rat Insulin ELISA
Kit, Catalog no: 90060, Crystal Chem, USA), adiponectin
(Rat ADP / Acrp 30 ELISA Kit, Catalog no: E-EL-R0329,
Elabscience Biotechnology Co. Ltd., China), resistin (Rat
RTN ELISA Kit, Catalog no. E-EL-R0614, Elabscience
Biotechnology Co. Ltd., China), leptin (Rat LEP ELISA
Kit, Catalog no. E-EL-R0582, Elabscience Biotechnology
Co. Ltd., China), and total antioxidant capacity marker
(TAC) (Total Antioxidant Capacity Assay Kit, Catalog
no: ab65329, Abcam Company, United Kingdom) were
determined following to manufacturer’s protocol by the
ELISA reader (Bio-Tek Instruments Inc., MWGt Lambda
Scan 200).
Homeostatic Model Assessment for insulin resistance
(HOMA-IR) and β-cell activity (HOMA-β) were

1580

calculated according to the following formula using with
the determined glucose and insulin values determined in
the study.
HOMA-IR: (Glucose × Insulin) / 405,
HOMA-β: (360 × Insulin) / (Glucose − 63).
2.6. Statistical analysis
The data were analyzed on SPSS 25.0 (SPSS, Inc., Chicago,
IL, USA) software, and all values were evaluated as median
[interquartile range (IQR)]. Statistical significance between
groups was tested using the Kruskal-Wallis and post hoc
Dunn-Bonferoni test. The data was considered statistically
significant at p < 0.05.
3. Results
The changes in various biochemical parameters after
lansoprazole (15 and 30 mg / kg / day, SC) and albendazole
(5 and 10 mg / kg / day, oral) treatment in experimental
T2D are illustrated Table 1. The endocrinological data are
presented in Table 2 and HOMA results are presented in
Table 3.
The glucose, HbA1c, triglyceride, and LDL values in the
diabetes group increased compared to the control group (p
< 0.05). Also, leptin and HOMA-IR levels increased, while
insulin and HOMA-β levels decreased in the diabetes
control group.
The low-dose albendazole treatment (LDAT) partially
decreased glucose, HbA1c, triglyceride, and leptin levels.
However, LDAT significantly decreased LDL level and
increased insulin and HOMA-β levels compared to diabetes
control group (p < 0.05).
The low-dose lansoprazole treatment (LDLT) decreased
partially triglyceride level and increased insulin level
however the high-dose lansoprazole treatment (HDLT)
significantly increased insulin level compared to diabetes
control group (p < 0.05). Although there were statistically
significant changes in AST, ALT, urea, and creatinine values,
these values were within the reported ranges for rats.
The insulin levels in the LHLT and LDAT groups were
similar to healthy control group level. Besides, leptin and
HOMA-β levels in the LDAT group were similar to healthy
control group level.
Although there were no statistically significant
differences in the treatment groups compared to the
diabetes control group for adiponectin and resistin, its level
in LDAT and high-dose albendazole treatments (HDAT)
groups were higher 209% and 161% than diabetes control
group, respectively (p > 0.05). The resistin levels decreased
significantly in LDAT and HDAT, LDLT groups (p < 0.05,
Table 2).
4. Discussion
Many studies have shown that AMPK activation is a key
mechanism in antidiabetic treatment [12,25]. Some
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Table 1. Effect of lansoprazole (15 and 30 mg/kg, SC) and albendazole (5 and 10 mg/kg/day, oral) treatment on biochemical parameters
in type 2 diabetic rats [median (IQR)].

Parameters

Healthy
control

Diabetes
control

Diabetes +
Low-dose
Lansoprazole

Diabetes +
High-dose
Lansoprazole

Diabetes +
Low-dose
Albendazole

Diabetes +
High-dose
Albendazole

Glucose (mg/dL)

129.5
(122.5–158.8)

486.5 #
(295.8–522.8)

467.0 #
(430.5–469.5)

477.0 #
(473.0–493.0)

221.5
(187.3–287.5)

433.0 #
(206.5–492.5)

HbA1c (%)

5.3
(5.0–5.5)

12.1 #
(7.3–12.7)

12.0 #
(11.5–13.1)

12.0 #
(11.4–12.7)

7.15
(6.0–9.3)

10.5 #
(8.2–11.1)

Triglycerides (mg/dL)

171.0
(149.5–183.3)

435.5 #
(387.5–557.0)

484.0
(143.5–635.0)

457.0 #
(271.0–536.5)

356.5
(197.5–472.3)

465.5 #
(432.5–681.5)

Cholesterol (mg/dL)

71.0
(67.0–99.3)

139.0
(72.3–334.8)

86.0
(76.5–92.5)

77.0
(72.5–227.5)

77.5
(72,5–83.0)

108.0
(87.0–187.5)

HDL (mg/dL)

50.0
(47.8–74.3)

45.0
(36.5–52.8)

34.0
(26.0–57.5)

30.0
(28.5–39.5) #

45.5
(42.8–55.3)

38.0
(31.5–58.0)

LDL (mg/dL)

7.69
(6.0–9.0)

19.5 #
(14.5–47.8)

21.0 #
(15.5–32.0)

20.0 t
(18.0–30.0)

11.0 *
(10.3–12.8)

22.4 #
(13.5–33.5)

AST (U/L)

136.5
(106.8–149.0)

67.5 #
(39.0–99.0)

102.0
(91.0–124.5)

88.0 t
(60.0–99.0)

81.0 #
(70.3–95.8)

75.0 #
(70.3–95.8)

ALT (U/L)

69.0
(58.3–75.5)

31.0 #
(25.8–46.8)

54.0 *
(34.5–61.5)

48.0
(34.5–61.5)

28.0 #
(23.3–40.0)

37.0 #
(28.0–50.0)

Urea (mg/dL)

45.0
(42.8–53.5)

43.0
(35.0–48.8)

41.0
(36.5–76.5)

32.0 *
(29.5–36.5)

38.5 #
(30.5–45.0)

39.0 #
(30.5–42.0)

Creatinine (mg/dL)

0.50
(0.46–0.54)

0.55
(0.49–0.60)

0.61 t, *
(0.57–0.63)

0.59 #
(0.57–0.61)

0.53
(0.50–0.55)

0.54 #
(0.50–0.62)

TAS (nmol)

1.05
(1.0–1.31)

1.05
(1.05–1.15)

1.08
(1.02–1.23)

1.09
(1.0–1.17)

1.18
(1.13–1.25)

1.08
(1.05–1.11)

# denotes significant difference vs. healthy control group at p ˂ 0.05.
* denotes significant difference vs. diabetes control group at p ˂ 0.05.
HDL: High density cholesterol, LDL: Low density cholesterol, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, HbA1c
(%): Hemoglobin A1c, TAS: Total antioxidant status.

benzimidazoles have been reported to have antidiabetic
effects by mainly activation of AMPK and PPAR,
inhibition of α-amylase and α-glucosidase enzymes and
other antidiabetic mechanisms.[10,26-28]. However, these
effects on AMPK may vary depending on the dose, the
ratio of binding to the AMPK, and activating different
subunits of AMPK [5]. Therefore, the benzimidazoles can
be considered as multitarget antidiabetic agents.
Furthermore, some benzimidazole molecules cause
regeneration of pancreas β cell, and the regulation of
adipose tissue [21,22,26,27]. It was emphasized that
telmisartan and lansoprazole, benzimidazole derivatives,
could be used as an antidiabetic in the treatment of T2D
by activating PPAR [27]. Other benzimidazole derivatives
compound 991 and lansoprazole have increased glucose
transport into tissues by AMPK activation or other

mechanism [22,29,30]. Metformin contributes to the
anthelmentic effect of albendazole by providing AMPK
activation in the larval period of Echinococcus granulosus
[31].
In the present study, the LDAT may prevent
gluconeogenesis and increase the effects of glucose
transporters by providing the AMPK activation in liver
and skeletal muscles. Also, the effects of albendazole on
the inhibition of α-amylase and α-glucosidase may have
contributed to its antidiabetic effect. In the literature, the
antidiabetic effects of benzimidazoles have been reported
to be dose-dependent, and the LDAT may have resulted
partially decrease in glucose and HbA1c in the current
study. In addition, the LDAT and LDLT can cause partially
the reduction in triglyceride levels by suppressing lipogenic
genes and AMPK activation. The LDAT may regulate
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Table 2. Effect of lansoprazole (15 and 30 mg/kg, SC) and albendazole (5 and 10 mg/kg/day, oral) treatment on endocrinological
parameters in type 2 diabetic rats [median (IQR)].

Parameters

Healthy
control

Diabetes
control

Diabetes +
Low-dose
Lansoprazole

Diabetes +
High- dose
Lansoprazole

Diabetes +
Low- dose
Albendazole

Diabetes +
High- dose
Albendazole

Insulin (ng/mL)

1.30
(1.16–1.69)

0.93 #
(0.85–0.98)

1.19
(1.06–1.29)

1.42 *
(0.98–1.54)

1.41 *
(1.34–1.65)

1.18
(1.05–1.27)

Adiponectin (pg/mL)

128.0
(58.5–162.5)

53.0
(30.8–131.5)

7.0
(0–118.5)

0
(0–56)

79.0
(45.5–458)

175.0
(28.3–342)

Resistin (ng/mL)

0.19
(0.6–2.84)

4.10
(1.74–5.94)

0
(0–2.39)

0
(0–8.30)

0.63
(0.38–1.83)

0
(0–0.82)

Leptin (ng/mL)

1.49
(0.27–2.24)

38.2 #
(6.63–56.9)

9.41 #
(6.83–19.26)

7.05 t
(3.65–20.8)

3.32
(2.60–7.20)

8.48 #
(3.27–22.9)

# denotes significant difference vs. healthy control group at p ˂ 0.05.
* denotes significant difference vs. diabetes control group at p ˂ 0.05.
Table 3. Effect of lansoprazole (15 and 30 mg/kg SC) and albendazole (5 and 10 mg/kg/day, oral) treatment on HOMA
parameters in type 2 diabetic rats [median (IQR)].

Parameters

Healthy
control

Diabetes
control

Diabetes +
Low-dose
Lansoprazole

Diabetes +
High- dose
Lansoprazole

Diabetes +
Low- dose
Albendazole

Diabetes +
High- dose
Albendazole

HOMA-IR

11.19
(10.4–12.7)

26.37 #
(25.9–27.8)

32.27 #
(29.2–35.8)

27.45 #
(16.8–38.8)

19.52 #
(16.3–37.7)

21.0 #
(14.0–31.0)

HOMA–β

160.4
(102.5–235.8)

19.4 #
(16.1–21.4)

26.5 #
(22.5–27.7)

36.0 #
(28.0–138.2)

78.5*
(28.0–138.2)

48.03 #
(25.4–73.7)

# denotes significant difference vs. healthy control group at p ˂ 0.05.
* denotes significant difference vs. diabetes control group at p ˂ 0.05.

lipoprotein lipase in muscles by activation of the PPAR
pathway and LDAT significantly decreased LDL level and
partially increased HDL level. However, the short duration
of the current study and the feeding of HFD (strong
diabetic and lipidemic effects) during the study may have
masked the antidiabetic treatments.
Biochemical parameters of the present study are
observed to be within the reference range reported for rats
[32,33] although there are statistical differences between
groups in ALT, AST, creatinine, and urea values. In the
present study, the biochemical changes show that there are
no side effects of the drugs used for treatment in diabetic
rats.
The LDLT and HDLT significantly increased insulin
levels compared to diabetes group in the present study. This
effect may occur as a result of β cell regeneration. Because
the treatment provides regeneration of β cell through
activation of PPARγ and AMPK [3,8,22]. HOMA-β, an
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indicator of B cell functionality, was significantly higher
in the low-dose albendazole treatment group from the
diabetes group. This shows that LDAT may provide
regeneration of β cells through more than one antidiabetic
pathway.
Adiponectin levels has negative correlation, while
leptin and resistin levels has positive correlation with
insulin resistance in diabetic individuals [34]. The increase
of leptin level induces the formation of free oxygen radicals.
This situation triggers hyperglycemia, adiponectin level
and leads to insulin resistance [22]. In the present study,
the positive effect of LDAT via PPAR and AMPK effects
on insulin resistance may cause the decrease in leptin
and resistin levels and the increase in adiponectin levels.
However, insulin resistance may be inadequately treated by
lansoprazole treatments, as the leptin level did not decrease
enough in the current study. As lipid-lowering effects of
higher doses of lansoprazole treatments have been reported

DİK et al. / Turk J Med Sci
[22,23], the albendazole treatments might prevented the
increase of leptin level in the current study. This effect may
be reduction of adipose tissue mass because it decreased
the leptin synthesizes in adipose tissue [5,6]. Therefore, the
percentage changes in adiponectin level could be caused by
the regulator role of insulin in fat cells and the differences
in the effects of treatment on organs [35,36]. The positive
effects of albendazole on insulin and the short duration of
treatment for diabetes may have caused partial changes
in adiponectin level. Resistin is an important factor for
insulin resistance; however, its expression reportedly
changed in two different directions (increase / decrease)
by treatments in different studies [35,36]. In the current
study, the low-dose albendazole treatments may decrease
the insulin resistance and hyperlipidemia through AMPK,
PPARγ, and other pathways.
Metformin has been caused a nonsignificant change in
HOMA-IR, although it has been activated the AMPK in
the obese mice [37]. Also, berberine was reported to be
antidiabetic effects by AMPK activation and decreased
HOMA-IR value and insulin resistance [38]. However, the
AMPK activation may produce different effects because
the activation of different subunits of AMPK has effective
at different ability and potential in different tissues [4,39].
Although all the treatments in the current study could not
change HOMA-IR levels, these treatments may prevent
gluconeogenesis in the liver and improve the pancreatic
regeneration by AMPK activation. This situation can be
confirmed by the increase in HOMA-β and insulin levels,
in particularly albendazole treatments groups.
In conclusion, new studies are carried out to show that
different benzimidazole derivatives may have antidiabetic
effects through AMPK, PPARγ, α-glucosidase, and other

pathways. Structural compatibility of benzimidazoles on
antidiabetic mechanisms is especially important [28,40,41].
The AMPK and PPARγ activation have been considered
as alternative important targets for the treatment of T2D
and obesity in recent years. The detailed research with
benzimidazole has not been conducted yet, because
antidiabetic mechanisms of benzimidazoles are just under
investigation. The differences between albendazole and
lansoprazole may have been caused by the difference in
the 3-dimensional structure of benzimidazoles that is
important for AMPK-drug interaction, the dose of the
drugs and activation of AMPK and PPARγ in different
organs.
Further studies including molecular and biochemical
mechanisms, pharmacodynamics, molecular docking,
and pharmacophore model is necessary to determine the
antidiabetic effect of various benzimidazole (particularly
albendazole) at different doses in T2D treatment. In
addition, comparative studies between AMPK activator
benzimidazoles and antidiabetic drugs such as metformin
and thiazolidinediones will contribute to the effective
antidiabetic treatment in future.
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